TherapeuticsMD, Inc. (TXMD)
NASDAQ: TXMD · Real-Time Price · USD
2.060
+0.050 (2.49%)
Oct 9, 2026, 4:00 PM EDT - Market closed
TherapeuticsMD Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3.27 | 3.02 | 1.76 | 1.3 | 69.96 | 2.57 | |
Revenue Growth | 27.78% | 71.61% | 35.25% | -98.14% | 2619.12% | -96.03% |
Cost of Revenue | - | - | - | - | 1.4 | 1.4 |
Gross Profit | 3.27 | 3.02 | 1.76 | 1.3 | 68.57 | 1.17 |
Selling, General & Admin | 4.64 | 5.01 | 4.74 | 8.9 | 56.71 | 72.75 |
Operating Expenses | 5.02 | 5.39 | 5.25 | 9.83 | 57.9 | 72.75 |
Operating Income | -1.75 | -2.37 | -3.49 | -8.52 | 10.66 | -71.58 |
Interest & Investment Income | 0.19 | 0.14 | 0.14 | - | - | - |
Other Non Operating Income (Expenses) | 1.4 | 1.75 | 2.28 | 0.78 | -0.12 | 0.27 |
EBT Excluding Unusual Items | -0.16 | -0.48 | -1.08 | -7.74 | 10.55 | -71.31 |
Merger & Restructuring Charges | - | - | - | - | -9.47 | - |
Asset Writedown | -0.1 | -0.18 | -1.27 | - | - | - |
Other Unusual Items | - | - | - | - | - | -8 |
Pretax Income | -0.26 | -0.65 | -2.34 | -7.74 | 1.07 | -79.31 |
Income Tax Expense | 0.03 | - | -0.03 | -0.04 | - | - |
Earnings From Continuing Operations | -0.3 | -0.65 | -2.31 | -7.7 | 1.07 | -79.31 |
Earnings From Discontinued Operations | 0.08 | 0.08 | 0.13 | -2.58 | 110.92 | -93.11 |
Net Income | -0.22 | -0.57 | -2.18 | -10.28 | 112 | -172.42 |
Net Income to Common | -0.22 | -0.57 | -2.18 | -10.28 | 112 | -172.42 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 12 | 12 | 12 | 10 | 9 | 8 |
Shares Outstanding (Diluted) | 12 | 12 | 12 | 10 | 9 | 8 |
Shares Change | 0.23% | 0.32% | 10.45% | 11.48% | 17.66% | 44.39% |
EPS (Basic) | -0.02 | -0.05 | -0.19 | -0.98 | 12.41 | -21.66 |
EPS (Diluted) | -0.02 | -0.05 | -0.19 | -0.99 | 11.95 | -21.66 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 3.12 | 2.42 | 0.73 | -48.14 | -4.08 | -142.73 |
Free Cash Flow Per Share | 0.27 | 0.21 | 0.06 | -4.61 | -0.43 | -17.93 |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 98.00% | 45.51% |
Operating Margin | -53.55% | -78.33% | -198.30% | -654.61% | 15.24% | -2781.85% |
Profit Margin | -6.64% | -18.83% | -123.85% | -789.40% | 160.08% | -6700.93% |
Free Cash Flow Margin | 95.41% | 80.21% | 41.57% | -3697.46% | -5.83% | -5547.10% |
EBITDA | -1.37 | -1.98 | -2.98 | -8.08 | 11.86 | -70.84 |
EBITDA Margin | -41.87% | -65.62% | -169.39% | - | 16.95% | - |
D&A For EBITDA | 0.38 | 0.38 | 0.51 | 0.44 | 1.19 | 0.74 |
EBIT | -1.75 | -2.37 | -3.49 | -8.52 | 10.66 | -71.58 |
EBIT Margin | -53.55% | -78.33% | -198.30% | - | 15.24% | - |
Revenue as Reported | - | - | - | - | 69.96 | 2.57 |